CompletedNot Applicable

Evaluation of IFNγ and Inflammatory Mediators in Patients With Hemophagocytic Lymphohistiocytosis

United States14 participantsStarted 2016-12-14

Plain-language summary

This observational study is designed to provide a better understanding of the potential use of interferon gamma (IFNγ) and IFNγ-inducible chemokines as markers of HLH disease activity in adults, and the potential of IFNγ to represent a therapeutic target.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients \>=18 years old diagnosed with active HLH as established by the treating physician. * HLH forms of unknown origin or secondary to infections or rheumatologic disorders. * Should the diagnosis of primary HLH or malignancy become apparent after inclusion, the data collected will be analyzed separately as additional cohorts. * The patient must have consented to the use of their clinical data for research purposes at the site. Exclusion Criteria: * Patients with primary HLH (diagnosed by the presence of homozygous mutations in a known HLH causative gene) and secondary HLH due to malignancy are excluded.

What they're measuring

Mean Serum Concentration of Inflammatory Biomarker - C-X-C Chemokine Ligand 10 (CXCL10)

Timeframe: 11 months

Mean Serum Concentration of Inflammatory Biomarker - C-X-C Chemokine Ligand 9 (CXCL9)

Timeframe: 11 months

Mean Serum Concentration of Inflammatory Biomarker - Interferon Gamma (IFNg)

Timeframe: 11 months

Mean Serum Concentration of Inflammatory Biomarker - Interleukin 10 (IL-10)

Timeframe: 11 months

Mean Serum Concentration of Inflammatory Biomarker - Interleukin 1 Beta (IL-1B)

Timeframe: 11 months

Mean Serum Concentration of Inflammatory Biomarker - Interleukin 6 (IL-6)

Timeframe: 11 months

Mean Serum Concentration of Inflammatory Biomarker - Neopterin

Timeframe: 11 months

Mean Serum Concentration of Inflammatory Biomarker - Tumor Necrosis Factor Alpha (TNFa)

Trial details

NCT IDNCT06047210

SponsorSwedish Orphan Biovitrum

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2019-10-30

Results submitted2023-10-10

View on ClinicalTrials.gov More Hemophagocytic Lymphohistiocytoses trials

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

What they're measuring

Mean Serum Concentration of Inflammatory Biomarker - C-X-C Chemokine Ligand 10 (CXCL10)

Timeframe: 11 months

Mean Serum Concentration of Inflammatory Biomarker - C-X-C Chemokine Ligand 9 (CXCL9)

Timeframe: 11 months

Mean Serum Concentration of Inflammatory Biomarker - Interferon Gamma (IFNg)

Timeframe: 11 months

Mean Serum Concentration of Inflammatory Biomarker - Interleukin 10 (IL-10)

Timeframe: 11 months

Mean Serum Concentration of Inflammatory Biomarker - Interleukin 1 Beta (IL-1B)

Timeframe: 11 months

Mean Serum Concentration of Inflammatory Biomarker - Interleukin 6 (IL-6)

Timeframe: 11 months

Mean Serum Concentration of Inflammatory Biomarker - Neopterin

Timeframe: 11 months

Mean Serum Concentration of Inflammatory Biomarker - Tumor Necrosis Factor Alpha (TNFa)